Vol. 283, Issue 5, G1062-G1073, November 2002
Molecular and functional analysis of glutamine uptake in
human hepatoma and liver-derived cells
Barrie P.
Bode1,3,
Bryan C.
Fuchs3,
Bryan P.
Hurley1,
Jennifer L.
Conroy1,
Julie E.
Suetterlin3,
Kenneth K.
Tanabe1,
David B.
Rhoads2,
Steve F.
Abcouwer1, and
Wiley W.
Souba1
1 Surgical Oncology Research Laboratories,
Department of Surgery and 2 Pediatric Endocrinology,
Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts 02114; and 3 Department of Biology,
Saint Louis University, St. Louis, Missouri 63103 - 2010
Human hepatoma cells take up
glutamine at rates severalfold faster than the system N-mediated
transport rates observed in normal human hepatocytes. Amino acid
inhibition, kinetic, Northern blotting, RT-PCR, and restriction enzyme
analyses collectively identified the transporter responsible in six
human hepatoma cell lines as amino acid transporter B0
(ATB0), the human ortholog of rodent ASCT2. The majority of
glutamine uptake in liver fibroblasts and an immortalized human liver
epithelial cell line (THLE-5B) was also mediated by ATB0.
The 2.9-kb ATB0 mRNA was equally expressed in all cell
lines, whereas expression of the system A transporters ATA2 and ATA3
was variable. In contrast, the system N isoforms (SN1 and SN2) were
expressed only in well-differentiated hepatomas. ATB0 mRNA
was also expressed in cirrhotic liver and adult and pediatric liver
cancer biopsies but was not detectable in isolated human hepatocytes or
fetal liver. Although the growth of all hepatomas was glutamine
dependent, competitive inhibition of ATB0-mediated
glutamine uptake blocked proliferation only in poorly differentiated
cells lacking SN1 or SN2 expression and exhibiting low glutamine
synthetase mRNA levels.
amino acid transporter B0; ASCT2; SN1; SN2; hepatocellular carcinoma; transport; system A